

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on January 18, 2006

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

IFW
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1633
Patent Application
Docket No. USF-T144X
Serial No. 10/049,502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Maria B. Marvich, Ph.D.
Art Unit : 1633
Applicant : Said M. Sebt
Serial No. : 10/049,502
Filed : February 13, 2002
Conf. No. : 7653
For : RhoB as a Suppressor of Cancer Cell Growth and Cell Transformation

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

01/23/2006 HDEHES1 00000048 190065 10049502
01 FC:1806 180.00 DA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:


In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicant has not submitted a copy of the published U.S. application cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the

mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (3 pages); copies of some references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/049,502
				Filing Date	February 13, 2002
				First Named Inventor	Said M. Sebti
				Art Unit	1633
				Examiner Name	Maria B. Marvich, Ph.D.
Sheet	1	of	3	Attorney Docket Number	USF-T144X

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2004-0171547 A1	09-02-2004	Sebti	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/049,502	
			Filing Date	February 13, 2002	
			First Named Inventor	Said M. Sebti	
			Group Art Unit	1633	
			Examiner Name	Maria B. Marvich, Ph.D.	
Sheet	2	of	3	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ADAMSON, P. <i>et al.</i> "Post-translational modifications of p21 ^{ras} proteins" <i>J Biol Chem</i> , 1992, 267:20033-20038.	
	R2	ADNANE, J. <i>et al.</i> "RhoB, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1" <i>J Biol Chem</i> , 2002, 277:8500-8507.	
	R3	ARMSTRONG, S.A. <i>et al.</i> "CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB" <i>J Biol Chem</i> , 1995, 270:7864-7868.	
	R4	BARON, R. <i>et al.</i> "RhoB prenylation is driven by the three carboxylterminal amino acids of the protein: Evidenced <i>in vivo</i> by an anti-farnesyl cysteine antibody" <i>Proc Natl Acad Sci USA</i> , 2000, 97:11626-11631.	
	R5	CHANG, F. <i>et al.</i> "Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention" <i>Leukemia</i> , 2003, 17:1263-1293.	
	R6	CHARDIN, P. <i>et al.</i> "Coding sequence of human <i>rho</i> cDNAs clone 6 and clone 9" <i>Nucleic Acids Res.</i> 1988, 16: 2717.	
	R7	CLARK, E.A. <i>et al.</i> "Genomic analysis of metastasis reveals an essential role for RhoC" <i>Nature</i> , 2000, 406:532-535.	
	R8	DOWNWARD, J. "Targeting Ras signaling pathways in cancer therapy" <i>Nat Rev Cancer</i> , 2003, 3:11-22.	
	R9	FORGET, M.A. <i>et al.</i> "The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers" <i>Clin Exp Metastasis</i> , 2002, 19(1):9-15.	
	R10	FRITZ, G. and KAINA, B. "Ras-related GTPase RhoB represses NF- κ B signaling" <i>J Biol Chem</i> , 2001, 276:3115-3122.	
	R11	FUKATA, M. <i>et al.</i> "Roles of Rho-family GTPases in cell polarisation and directional migration" <i>Curr Opin Cell Biol</i> , 2003, 15:590-597.	
	R12	GENBANK accession number X06820, "H. sapiens rhoB gene mRNA" October 24, 1996.	
	R13	GENBANK accession number CAA29968, "rhoB [Homo sapiens]" October 24, 1996.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/049,502
				Filing Date	February 13, 2002
				First Named Inventor	Said M. Sebti
				Group Art Unit	1633
				Examiner Name	Maria B. Marvich, Ph.D.
				Attorney Docket Number	USF-T144X
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	JIANG, K. <i>et al.</i> "Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis" <i>Mol Cell Biol</i> , 2004, 24:5565-5576.	
	R15	JIANG, K. <i>et al.</i> "EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation" <i>Oncogene</i> , 2004, 23:1136-1145.	
	R16	LEBOWITZ, P.F. <i>et al.</i> "Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription" <i>J Biol Chem</i> , 1997, 272:16093-16095.	
	R17	LIU, A-X. <i>et al.</i> "RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells" <i>Mol Cell Biol</i> , 2001, 21:6906-6912.	
	R18	MAZIERES, J. <i>et al.</i> "Loss of RhoB expression in human lung cancer progression" <i>Clin Cancer Res</i> , 2004, 10:2742-2750.	
	R19	NAKAMURA, T. <i>et al.</i> "Cloning of the RhoB gene from the mouse genome and characterization of its promoter region" <i>Biochem. Biophys. Res. Commun.</i> , 1996, 226(3):688-694.	
	R20	NOBES, C.D. and HALL, A. "Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia" <i>Cell</i> , 1995, 81:53-62.	
	R21	SYMONS, M. and RUSK, N. "Control of vesicular trafficking by Rho GTPases" <i>Curr Biol</i> , 2003, 13:R409-418.	
	R22	WANG, D-A and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor suppressive and apoptotic activities" Presentation at the American Association for Cancer Research, Anaheim, CA, April 16-20, 2005, abstract.	
	R23	WANG, D-A. and SEBTI, S.M. "Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities" <i>J. Biol. Chem.</i> , 2005, 280:19243-19249.	
	R24	WELSH, C.F. "Rho GTPases as key transducers of proliferative signals in G ₁ cell cycle regulation" <i>Breast Cancer Res Treat</i> , 2004, 84:33-42.	
	R		
	R		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.